Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advanced Viral Research
Advanced Viral Research granted U.S. patent for rheumatoid arthritis
August 18th, 2006
Advanced Viral Research Corp. (ADVR) announced that effective June 27, 2006, the company has received U.S. patent approval for treatment of rheumatoid arthritis by administering Product R (AVR118), a peptide-nucleic acid preparation. Rheumatoid arthritis, a chronic inflammatory illness, is an autoimmune disease in which the immune system attacks normal tissue components as if they were invading pathogens. This illness affects about 1% of the world's population. "We are excited that the U.S. Patent Office has granted us with this important patent," said Stephen M. Elliston, CEO and president of Advanced Viral Research. "With such a large population...
Source: Biotech Law Weekly (2006-08-18)
|
